JP2018518152A5 - - Google Patents

Download PDF

Info

Publication number
JP2018518152A5
JP2018518152A5 JP2017550493A JP2017550493A JP2018518152A5 JP 2018518152 A5 JP2018518152 A5 JP 2018518152A5 JP 2017550493 A JP2017550493 A JP 2017550493A JP 2017550493 A JP2017550493 A JP 2017550493A JP 2018518152 A5 JP2018518152 A5 JP 2018518152A5
Authority
JP
Japan
Prior art keywords
seq
antibody
acid sequence
equivalent
lhr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017550493A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018518152A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/024354 external-priority patent/WO2016160618A2/en
Publication of JP2018518152A publication Critical patent/JP2018518152A/ja
Publication of JP2018518152A5 publication Critical patent/JP2018518152A5/ja
Pending legal-status Critical Current

Links

JP2017550493A 2015-03-27 2016-03-25 充実性腫瘍を処置するためのlhrに指向されたcar t細胞治療 Pending JP2018518152A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562139623P 2015-03-27 2015-03-27
US62/139,623 2015-03-27
PCT/US2016/024354 WO2016160618A2 (en) 2015-03-27 2016-03-25 Car t-cell therapy directed to lhr for the treatment of solid tumors

Publications (2)

Publication Number Publication Date
JP2018518152A JP2018518152A (ja) 2018-07-12
JP2018518152A5 true JP2018518152A5 (enExample) 2019-05-09

Family

ID=57007252

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017550493A Pending JP2018518152A (ja) 2015-03-27 2016-03-25 充実性腫瘍を処置するためのlhrに指向されたcar t細胞治療

Country Status (9)

Country Link
US (3) US11136401B2 (enExample)
EP (1) EP3273994B1 (enExample)
JP (1) JP2018518152A (enExample)
CN (1) CN107530427A (enExample)
AU (1) AU2016243124A1 (enExample)
CA (1) CA2981142A1 (enExample)
ES (1) ES2904573T3 (enExample)
IL (1) IL254701A0 (enExample)
WO (1) WO2016160618A2 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016160618A2 (en) 2015-03-27 2016-10-06 University Of Southern California Car t-cell therapy directed to lhr for the treatment of solid tumors
WO2016197064A1 (en) 2015-06-04 2016-12-08 Epstein Alan L Lym-1 and lym-2 targeted car cell immunotherapy
CA3030683C (en) 2016-07-12 2023-11-21 Kite Pharma, Inc. Antigen binding molecules and methods of use thereof
US20200016201A1 (en) * 2016-09-23 2020-01-16 University Of Southern California Chimeric antigen receptors and compositions and methods of use thereof
EP3548055A4 (en) 2016-12-02 2020-08-19 University of Southern California SYNTHETIC IMMUNE RECEPTORS AND THEIR PROCESSES FOR USE
CN117959418A (zh) * 2017-03-13 2024-05-03 波赛达治疗公司 用于选择性消除和替换造血干细胞的组合物和方法
CN107354199A (zh) * 2017-07-04 2017-11-17 武汉波睿达生物科技有限公司 一种检测靶向cd30的cart细胞中car表达的荧光定量试剂盒
WO2019060713A1 (en) * 2017-09-22 2019-03-28 Kite Pharma, Inc. ANTIGEN-BINDING MOLECULES AND METHODS OF USE THEREOF
EP3675878A4 (en) 2017-10-02 2021-06-16 Fred Hutchinson Cancer Research Center LUTEINIZING HORMONE RECEPTOR BINDERS AND LUTEINIZING HORMONAGONISTS FOR IDENTIFICATION, EXPANSION, ABLATION AND MODIFICATION OF PRIMITIVE STEM CELL POPULATIONS
US11319380B2 (en) 2018-06-04 2022-05-03 Precigen, Inc. MUC16 specific chimeric antigen receptors and uses thereof
CA3111087A1 (en) * 2018-08-29 2020-03-05 Nanjing Legend Biotech Co., Ltd. Anti-mesothelin chimeric antigen receptor (car) constructs and uses thereof
CN113227792A (zh) * 2018-10-13 2021-08-06 纪念斯隆-凯特琳癌症中心 识别和治疗处于car t细胞疗法反应不佳风险中的受试者的方法和组合物
WO2020142780A1 (en) * 2019-01-06 2020-07-09 Tocagen Inc. Car t cell methods and constructs
CA3129501A1 (en) 2019-02-15 2020-08-20 University Of Southern California Lym-1 and lym-2 antibody compositions and improved car constructs
EP3980453A4 (en) * 2019-06-07 2023-07-05 The Trustees of the University of Pennsylvania Dual car expressing t cells individually linked to cd28 and 4-1bb
EP4087590A4 (en) * 2020-01-12 2024-05-15 Vanderbilt University HUMAN ANTIBODIES AGAINST CRIMEAN-CONGO HEMORRHAGIC FEVER VIRUS
US20240173257A1 (en) * 2020-07-07 2024-05-30 THERMOSOME GmbH Liposome formulations
US20230382978A1 (en) * 2020-10-15 2023-11-30 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Antibody specific for sars-cov-2 receptor binding domain and therapeutic methods
AR124414A1 (es) 2020-12-18 2023-03-22 Century Therapeutics Inc Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable
US12144827B2 (en) 2021-02-25 2024-11-19 Lyell Immunopharma, Inc. ROR1 targeting chimeric antigen receptor
CN113156142B (zh) * 2021-04-16 2024-09-27 苏州才博医学科技有限公司 一种针对异体cart细胞特异性抗体的检测方法
WO2025117530A2 (en) * 2023-11-27 2025-06-05 The Trustees Of Columbia University In The City Of New York Tmem106b(120-254) aggregate-binding antibody

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US707993A (en) 1901-05-16 1902-08-26 Clinton J Warren Machine for corking bottles.
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
EP0436597B1 (en) 1988-09-02 1997-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
AU7247191A (en) 1990-01-11 1991-08-05 Molecular Affinities Corporation Production of antibodies using gene libraries
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
ATE414768T1 (de) 1991-04-10 2008-12-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
WO1992022324A1 (en) 1991-06-14 1992-12-23 Xoma Corporation Microbially-produced antibody fragments and their conjugates
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1995015982A2 (en) 1993-12-08 1995-06-15 Genzyme Corporation Process for generating specific antibodies
DE69534347T2 (de) 1994-01-31 2006-05-24 Trustees Of Boston University, Boston Bibliotheken aus Polyklonalen Antikörpern
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
GB9416721D0 (en) 1994-08-18 1994-10-12 Short Brothers Plc A bias yarn assembly forming device
US5712149A (en) 1995-02-03 1998-01-27 Cell Genesys, Inc. Chimeric receptor molecules for delivery of co-stimulatory signals
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
ES2176484T3 (es) 1995-08-18 2002-12-01 Morphosys Ag Bancos de proteinas/(poli)peptidos.
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
US6924123B2 (en) 1996-10-29 2005-08-02 Oxford Biomedica (Uk) Limited Lentiviral LTR-deleted vector
ES2327382T3 (es) 1999-07-20 2009-10-29 Morphosys Ag Metodos para presentar (poli)peptidos/proteinas en particulas de bacteriofagos a traves de enlaces disulfuro.
AT411997B (de) 1999-09-14 2004-08-26 Baxter Ag Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate
DE60025022D1 (de) 1999-09-27 2006-01-26 Clifford L Librach Nachweis von hla-g
KR20030032922A (ko) 2000-02-24 2003-04-26 싸이트 테라피스 인코포레이티드 세포의 동시 자극 및 농축
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US7419829B2 (en) 2000-10-06 2008-09-02 Oxford Biomedica (Uk) Limited Vector system
IL157335A0 (en) 2001-03-13 2004-02-19 Novartis Ag Lentiviral packaging constructs
WO2004035537A2 (en) 2002-10-16 2004-04-29 Euro-Celtique S.A. Antibodies that bind cell-associated ca 125/o772p and methods of use thereof
SI1583830T1 (sl) 2003-01-07 2006-12-31 Symphogen As Postopek za pripravo rekombinantnih poliklonskih proteinov
CA2518552A1 (en) 2003-03-11 2004-09-23 Genentech, Inc. Novel compositions and methods for the treatment of immune related disease
GB0408449D0 (en) 2004-04-15 2004-05-19 Banerjee Subhasis Diagnostic and therapeutic applications of soluble lhcge protein
EP1789087A4 (en) 2004-08-20 2009-10-21 Univ California GENETICALLY MODIFIED ANTIBODY FRAGMENT WHICH LINKS TO ANTIGEN IRREVERSIBLELY
CN1331887C (zh) 2004-08-20 2007-08-15 上海美恩生物技术有限公司 抗hla-dr10的淋巴瘤特异性嵌合单抗
US7811563B2 (en) 2004-10-25 2010-10-12 Northwestern University Anti-addl antibodies and uses thereof
WO2007058725A2 (en) 2005-10-12 2007-05-24 The Regents Of The University Of California Engineered antibody fragment that irreversibly binds an antigen
US7858752B2 (en) 2006-12-05 2010-12-28 Abbott Laboratories Recombinant antibodies against hepatitis C virus and methods of obtaining and using same
EP2331566B1 (en) 2008-08-26 2015-10-07 City of Hope Method and compositions for enhanced anti-tumor effector functioning of t cells
CA2740900C (en) 2008-11-03 2019-09-24 Alethia Biotherapeutics Inc. Antibodies that specifically block the biological activity of a tumor antigen
US8673314B2 (en) 2009-05-26 2014-03-18 Mount Sinai School Of Medicine Monoclonal antibodies against influenza virus generated by cyclical administration and uses thereof
WO2010141630A1 (en) * 2009-06-03 2010-12-09 University Of Southern California Compositions and methods for treatment of cancer by disrupting the lh/lhr signaling pathway
WO2011016238A1 (en) * 2009-08-06 2011-02-10 Immunas Pharma, Inc. Antibodies that specifically bind to a beta oligomers and use thereof
US9243057B2 (en) * 2010-08-31 2016-01-26 The Regents Of The University Of California Antibodies for botulinum neurotoxins
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
US9233125B2 (en) * 2010-12-14 2016-01-12 University Of Maryland, Baltimore Universal anti-tag chimeric antigen receptor-expressing T cells and methods of treating cancer
EP2817330B1 (en) 2012-02-22 2020-07-08 The Trustees of the University of Pennsylvania Use of icos-based cars to enhance antitumor activity and car persistence
RU2766608C2 (ru) 2012-04-11 2022-03-15 Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез Химерные антигенные рецепторы, нацеленные на антиген созревания b-клеток
US20130280220A1 (en) * 2012-04-20 2013-10-24 Nabil Ahmed Chimeric antigen receptor for bispecific activation and targeting of t lymphocytes
CA2887129A1 (en) 2012-10-09 2014-04-17 Igenica, Inc. Anti-c16orf54 antibodies and methods of use thereof
EP2730588A1 (en) 2012-11-12 2014-05-14 Intelectys Antibodies and fragments thereof raised against the alpha-3 domain of HLA-G protein, methods and means for their preparation, and uses thereof
US9534044B2 (en) 2013-02-28 2017-01-03 United Arab Emirates University Alpha-synuclein antibodies and uses thereof
US20140348744A1 (en) * 2013-05-24 2014-11-27 Jacek K. Pinski Compositions and methods for regulating cancer-related signaling pathways
EP3037819A4 (en) 2013-08-23 2017-03-29 Fujita Health University Method of determining resistance to influenza virus
KR101605421B1 (ko) 2014-03-05 2016-03-23 국립암센터 B 세포 림프종 세포를 특이적으로 인지하는 단일클론항체 및 이의 용도
WO2016160618A2 (en) 2015-03-27 2016-10-06 University Of Southern California Car t-cell therapy directed to lhr for the treatment of solid tumors
WO2016174652A1 (en) 2015-04-30 2016-11-03 Technion Research & Development Foundation Limited Chimeric antigen receptors and methods of their use
WO2018154386A1 (en) 2017-02-21 2018-08-30 Eutilex Co., Ltd. Hla-dr car-t compositions and methods of making and using the same

Similar Documents

Publication Publication Date Title
JP2018518152A5 (enExample)
AU2023200608B2 (en) Anti-human papillomavirus 16 E7 T cell receptors
JP2018513687A5 (enExample)
JP2018511319A5 (enExample)
CN109843927B (zh) 抗b7-h3抗体、其抗原结合片段及其医药用途
JP2018524973A5 (enExample)
Inaguma et al. Construction and molecular characterization of a T-cell receptor-like antibody and CAR-T cells specific for minor histocompatibility antigen HA-1H
JP2009100745A5 (enExample)
JP7712338B2 (ja) ヒトがんの治療のためのモノクローナル抗体neo-201
JP5142265B2 (ja) 抗モータリン抗体のパラトープ及びエピトープ
RS57080B1 (sr) Identifikacija antigena povezanih sa tumorom za dijagnostiku i terapiju
EP3349792A1 (en) Compositions and methods for treating cancer via antagonism of the cd155/tigit pathway and tgf-
JP2020501512A5 (enExample)
JP2018529380A5 (enExample)
CN119185533A (zh) 新型免疫检查点抑制剂
CN116640216B (zh) 抗cd19抗体的抗体、抗cd22抗体的抗体及其应用
JP2021507877A5 (enExample)
JP7271446B2 (ja) Hla-g転写物およびアイソフォームおよびそれらの使用
JP2016514099A5 (enExample)
JP2015501146A5 (enExample)
Grøndahl-Rosado et al. NCR1+ cells in dogs show phenotypic characteristics of natural killer cells
JP2018199675A5 (enExample)
AU2019267050B2 (en) Epitope of regulatory T cell surface antigen and antibody specifically binding thereto
Hayes et al. ERBB3: A potential serum biomarker for early detection and therapeutic target for devil facial tumour 1 (DFT1)
JP2022538688A5 (enExample)